Global Hematology and Coagulation Testing Markets Report 2020 with Discussion of COVID-19
October 28, 2020 06:53 ET
|
Research and Markets
Dublin, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The "Hematology and Coagulation Markets (Lab-based and Decentralized Markets)" report has been added to ResearchAndMarkets.com's offering. Hematology and...
NIH Awards Prize to Hemex Health’s Non-Invasive Sickle Cell, Malaria, Anemia Rapid Test (“SMART”) Diagnostic Technology
October 26, 2020 08:00 ET
|
Hemex Health
PORTLAND, Ore., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Researchers from Hemex Health, Medtronic plc, Case Western Reserve University, and the University of Nebraska Medical Center’s International...
BioSyent Annonce L'Introduction du Nouveau FeraMAX® Pd
October 05, 2020 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, 05 oct. 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (« BioSyent », « la Société », Bourse de croissance : RX) a le plaisir d’annoncer l’introduction de FeraMAX® Pd, une nouvelle...
BioSyent Announces Introduction of New FeraMAX® Pd
October 05, 2020 08:00 ET
|
BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 05, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the introduction of FeraMAX® Pd, a new oral iron supplement...
FibroGen to Report Second Quarter 2020 Financial Results
July 23, 2020 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will...
FibroGen to Present at Upcoming Investor Conferences
May 27, 2020 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
May 08, 2020 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May...
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
March 02, 2020 16:01 ET
|
FibroGen, Inc
Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic...
FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease
December 23, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
December 02, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s...